Combination therapy targeting KRAS mutation could provide benefit to nearly a third of lung cancer patients, reveals a new study. The findings of the study are published in the journal iCancer Research/i.
Lung cancer is the second most common cancer found in both men and women. It is estimated there will be roughly 228,000 new lung cancer cases this year, and nearly 30% of those patients will have mutations in the KRAS pathway. This type of mutation makes cancer more aggressive and difficult to treat....
Combination therapy targeting KRAS mutation could provide benefit to nearly a third of lung cancer patients, reveals a new study. The findings of the study are published in the journal iCancer Research/i.
Lung cancer is the second most common cancer found in both men and women. It is estimated there will be roughly 228,000 new lung cancer cases this year, and nearly 30% of those patients will have mutations in the KRAS pathway. This type of mutation makes cancer more aggressive and difficult to treat....